Koppal SP Dr Anup A Shetty moves CAT over his sudden transfer

Bengaluru, Feb 12: Mohammed Nalapad, the rogue son of Karnataka Congress leader NA Harris, who is out on bail in a 2018 case of him bashing up a man at a pub, has now rammed his luxury car into vehicles, injuring four people on Bengaluru road.

The incident took place on Sunday on the Ballari Road where Nalapad was rash driving his car. The car hit a biker and an autorickshaw, injuring four people. He immediately got off his car and fled riding a friend's car.

The biker has suffered a fracture in his leg and is undergoing treatment at a hospital.

According to police, soon after the accident a man appeared before police to claim responsibility for the accident.

Ravikante Gowde, Joint Commissioner of Police said, "A man named Balakrishna came to surrender as the one who was driving the car. Investigation has, however, showed that it was Nalapad who was driving when he met with the accident. The investigating officer has issued him a notice to appear before the police."

BJP spokesperson S Prakash has said, "A case under the Goonda Act should be filed against Nalapad and the court should take cognisance of this and cancel his bail. The father has no control over son. He is a serial offender who is harming the public on a repeated basis."

Nalapad was earlier arrested in 2018 in the Bengaluru pub incident in which he and his associate bashed up the son of a prominent businessman in the city. Nalapad Harris is out on bail after remaining in judicial custody for three months in the case of attempt to murder after the 2018 midnight brawl.

Mangaluru, Mar 29: Dakshina Kannada Co-operative Milk Producers’ Union Limited in a statement announced that their milk collection centres across Dakshina Kannada and Udupi districts will be closed on March 29 and 30.

Due to a shortage of storage space with them, the Union has decided to stop collecting milk on these two days, according to the statement issued here on Saturday.

The sale/retail of milk and milk products won’t be affected in these two days.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.